IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1645

Examiner: To Be Assigned

Applicant(s):

Hu and Nepomnichy

Application No.:

09/971,121

Filed:

October 4, 2001

Title:

Novel Human Transporter Proteins and

Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0250-USA

Assistant Commissioner for Patents

Washington, D.C. 20231

Box DD

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.97(b), or
(Within three months of filing national application; or date of entry of international
application; or before mailing date of first office action on the merits; whichever
occurs last)

- under 37 CFR 1.97(c) together with either a:
 - Certification under 37 CFR 1.97(e), or
 - a \$240.00 fee under 37 CFR 1.17(p), or
 - (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- under 37 CFR 1.97(d) together with a:
 - ___ Certification under 37 CFR 1.97(e), and
 - ___ a petition under 37 CFR 1.97(d)(2)(ii), and
 - ___ a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).
 - (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

X Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.



24231

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

The Commissioner is hereby authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Lexicon Genetics Deposit Account No. 50-0892. A copy of this sheet is enclosed.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

January 28, 2002

Date

Jance K. Johnnow by David W. Hobber REZ. No. 41,071

Lance K. Ishimoto

Reg. No. 41,866

LEXICON GENETICS INCORPORATED

24231
PATENT_TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Hu and Nepomnichy

Application No.:

09/971,121

Filed:

October 4, 2001

Group Art Unit: 1645

Title:

Novel Human Transporter Proteins and

Examiner: To Be Assigned

Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0250-USA

Assistant Commissioner for Patents Washington, D.C. 20231 Box DD

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Information Disclosure Statement is submitted:

<u>X</u>	under 37 CFR 1.97(b), or
	(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
	under 37 CFR 1.97(c) together with either a: Certification under 37 CFR 1.97(e), or
	a \$240.00 fee under 37 CFR 1.17(p), or
	(After the CFR 1.97(b) time period, but before final action or notice of
	allowance, whichever occurs first)
	under 37 CFR 1.97(d) together with a:
	Certification under 37 CFR 1.97(e), and
	a petition under 37 CFR 1.97(d)(2)(ii), and
	a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).
	(Filed after final action or notice of allowance, whichever occurs first, but before
	payment of the issue fee)

Applicant(s) submit herewith Form PTO 1449-Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.



Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

The Commissioner is hereby authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Lexicon Genetics Deposit Account No. 50-0892. A copy of this sheet is enclosed.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

DAVID W. HBUER

January 28, 2002

Date

Jance K. Johnnor by David W. Shiller Ret. N. 41,071

Lance K. Ishimoto

Reg. No. 41,866

LEXICON GENETICS INCORPORATED

24231
PATENT_TRADEMARK OFFICE

1

Sheet

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Trademark Office; U.S. DEPARTMENT OF COMMERCE plays a valid OMB control number.

LEX-0250-USA

are required to respond to a collection of information unless Under the Paperwork Reduction Act of 1995, no pe Complete if Known Substitute for form 1449A/PTO 09/971,121 **Application Number INFORMATION DISCLOSURE Filing Date** Oct 4, 2001 **First Named Inventor** Hu STATEMENT BY APPLICANT 1645 Group Art Unit Not Yet Assigned **Examiner Name**

Attorney Docket Number

3

of

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.¹	U.S. Patent Document Kind Code² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	AA	4,215,051		Schroeder et al	07/29/80			
	AB	4,376,110		David et al	03/08/83			
	AC	4,594,595		Struckman	06/10/86			
	AD	4,631,211		Houghten	12/23/86			
	AE	4,713,326		Dattagupta et al	12/15/87			
	AF	4,873,191		Wagner et al	10/10/89			
	AG	4,946,778		Ladner et al	08/07/90			
	AH	5,198,344		Croop et al	03/30/93			
	Al	5,252,743		Barrett et al	10/12/93			
	AJ	5,272,057		Smulson et al	12/21/93			
	AK	5,424,186		Fodor et al	06/13/95			
	AL	5,445,934		Fodor et al	08/29/95			
	AM	5,459,127		Felgner et al	10/17/95			
	AN	5,556,752		Lockhart et al	09/17/96			
	AO	5,700,637		Southern	12/23/97			
	AP	5,723,323		Kauffman et al	03/03/98			
	AQ	5,744,305		Fodor et al	04/28/98			
	AR	5,830,721		Stemmer et al	11/03/98			
	AS	5,837,458		Minshull et al	11/17/98			
	AT	5,866,699		Smyth	02/02/99			
	AU	5,877,397		Lonberg et al	03/02/99			
	AV	5,948,767		Scheule et al.	09/07/99			
	AW	6,075,181		Kucherlapati et al	06/13/00			
	AX	6,080,842		Hillman et al	06/27/00			
	AY	6,110,490		Thierry	08/29/00	· 		
					<u> </u>			

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99. OMB 0651-0031 nt and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known 09/971,121 **Application Number INFORMATION DISCLOSURE** Oct 4, 2001 **Filing Date** STATEMENT BY APPLICANT Hu First Named Inventor FEB 0 4 2002 1645 Group Art Unit (use as many sheets as necessary) Not Yet Assigned **Examiner Name** 3 LEX-0250-USA of Attorney Docket Number Sheet 2

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	Т
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	י
	AZ	Bird et al, 1988, "Single-Chain Antigen-Binding Proteins", Science 242:423-426.	L
	ВА	Bitter et al, 1987, "Expression and Secretion Vectors for Yeast", Methods in Enzymology 153:516-544.	L
	BB	Colbere-Garapin et al, 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1-14.	
	ВС	Gautier et al, 1987, "α-DNA IV:α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physiochemical properties and poly (rA) binding", Nucleic Acids Research 15(16):6625-6641.	
	BD	Gordon, 1989, "Transgenic Animals", International Review of Cytology, 115:171-229.	L
	BE	Greenspan et al, 1993, "Idiotypes: structure and immunogenicity", FASEB Journal 7:437-444.	L
	BF	Gu et al, 1994, "Deletion of a DNA Polymerase β Gene Segment in T Cells Using Cell Type-Specific Gene Targeting", Science 265:103-106.	
	BG	Huse et al, 1989, "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science 246:1275-1281.	L
	вн	Huston et al, 1988, "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA 85:5879-5883.	
	ВІ	Inoue et al, 1987, "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase H", FEBS Letters 215(2):327-330.	
	BJ	Inoue et al, 1987, "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides", Nucleic Acids Research 15(15):6131-6149.	1
	ВК	Inouye & Inouye, 1985, "Up-promoter mutations in the lpp gene of Escherichia coli", Nucleic Acids Research 13(9):3101-3110.	
	BL	Janknecht et al, 1991, "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", PNAS 88:8972-8976.	
	ВМ	Kohler & Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature 256:495-497.	
	BN	Lakso et al, 1992, "Targeted oncogene activation by site-specific recombination in transgenic mice", Proc. Natl. Acad. Sci. USA 89:6232-6236.	
	во	Lavitrano et al, 1989, "Sperm Cells as Vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice", Cell 57:717-723.	
	BP	Lo, 1983, "Transformation by Iontophoretic Microinjection of DNA: Multiple Integrations without Tandem Insertions", Mol. Cell. Biology 3(10):1803-1814.	&
	BQ	Logan et al, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl Acad. Sci. USA 81:3655-3659.	1
	BR	Lowy et al, 1980, "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", Cell 22:817-823.	
	BS	Morrison et al, 1984, "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA 81:6851-6855.	
	вт	Mulligan & Berg, 1981, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78(4):2072-2076.	
	ВU	Neuberger et al, 1984, "Recombinant antibodies possessing novel effector functions", Nature 312:604-608.	\downarrow
	ВV	Nisonoff, 1991, "Idiotypes: Concepts and Applications", J. of Immunology 147:2429-2438.	
	вw	O'Hare et al, 1981, "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", Proc. Natl. Acad. Sci. USA 78(3):1527-1531.	

Approved for use through 10/31/99. OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE Patent

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
INE	ORMATION D	אפור	CI OSUBE	Application Number	09/971,121	(A)PA	
				Filing Date	Oct 4, 2001		
STATEMENT BY APPLICANT				First Named Inventor	Hu	C	
				Group Art Unit	1645	FEB 0 4 2002 &	
	(use as many sheets	as nec	essary)	Examiner Name	Not Yet Assigned	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	
Sheet	3	of	3	Attorney Docket Number	LEX-0250-USA	EN DADGE ARKE	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	ВХ	Ruther et al, 1983, "Easy identification of cDNA clones", EMBO Journal 2(10):1791-1794.	
	BY	Santerre et al, 1984, "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene 30:147-156.	
	BZ	Sarin et al, 1988, "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.	
	CA	Smith et al, 1983, "Molecular Engineering of the Autographa californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.	
	СВ	Stein et al, 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research 16(8):3209-3221.	
	СС	Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.	
	CD	Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.	
	CE	Thompson et al, 1989, "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targetin in Embryonic Stem Cells", Cell 56:313-321.	g
	CF	Van Der Putten et al, 1985, "Efficient insertion of genes into the mouse germ line via retroviral vectors", Proc. Natl. Acad. Sci. USA 82:6148-6152.	
	CG	Van Heeke et al, 1989, "Expression of Human Asparagine Synthetase in Escherichia coli", J. Biol. Chemistry 264(10):5503-5509.	
	СН	Ward et al, 1989, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", Nature 341:544-546.	
	CI	Wigler et al, 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 11:223-232	
	CJ	Wigler et al, 1980, "Transformation of mammalian cells with an amplifiable dominant-acting gene", Proc. Natl. Acad. Sci. USA 77(6):3567-3570.	

Examiner		Date	
Signature		Considered	
- 3	Control of the Contro		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.